Development of Actinobacillus pleuropneumoniae ApxI, ApxII, and ApxIII-specific ELISA methods for evaluation of vaccine efficiency.

Among the various vaccine against Actinobacillus pleuropneumoniae, subunit vaccine uses a recombinant protein from ApxI, ApxII, and ApxIII as vaccine antigens have shown good success in terms of security and protection. Therefore, subunit vaccines are being implemented around the world and the development of new subunit vaccines is actively being conducted. To evaluate the effectiveness of a subunit vaccine, it is important to measure the immune response to each toxin Apx separately. However, the cross-reactivity of antibodies makes it difficult to measure the immune reactivity specific to each toxin. 

In this study, region-specific antigen between toxins identified and cloned to solve this problem. Respectively antigenicity of recombinant proteins Hapten Conjugates Proteins demonstrated by Western blot. Using recombinant proteins, we developed Immunosorbent Assay (ELISA) enzyme-linked method that can detect immune response specific for each Apx toxins in laboratory guinea pigs. We suggest that the ELISA method developed in this study could be an important tool in the evaluation of the efficiency of vaccines and vaccine development.

The ΦCPG1 chlamydiaphage can infect Chlamydia trachomatis and significantly reduce its infectivity.

Recent years have seen a significant increase in the rate, antibiotic-resistant infections constantly from Chlamydia trachomatis (CT) infection, representing an increasingly serious public health threat. Currently there are no effective vaccines or antibodies available to treat CT, prompting the need for new treatment strategies. One potential solution to this problem is the use of ΦCPG1, a lytic phage that specifically chlamydia had more than 90% nucleotide sequence identity with other chlamydiaphages. 

Previous studies have shown VP1 capsid protein of ΦCPG1 shows http://gentaur-antibodies.com/ broad inhibitory activity against all serotypes CT, inhibiting the host cell toxicity mediated CT. Patients with CT infection demonstrated by antibodies against VP1 protein, suggesting that this phage or similar may be present in vivo in the context of CT infections, although none of the phage specifically detected to date. Given previous findings, we hypothesized that ΦCPG1 chlamydiaphage may be able to infect CT, thus inhibiting the growth and proliferation. 

To test this, we generate recombinant phage pGFP-ΦCPG1 which we used to explore the impact on CT and chlamydial conjunctivitis marmot (GPIC). We found that the insertion pGFP not change the packaging or infectivity ΦCPG1, and that this recombinant phage is capable of infecting CT and GPIC and inhibits CT and GPIC in a dose-dependent fashion. This inhibition was most pronounced during the middle and late stages of infection CT, interfere with reticular body (RB) to EB transition, leading to the formation of an enlarged BPR